Log In
Print
BCIQ
Print
Print this Print this
 

Trumenba (recombinant LP2086) (PF-05212366, PF-5212366, rLP2086)

Also known as: Meningococcal B vaccine, MnB rLP2086

  Manage Alerts
Collapse Summary General Information
Company Pfizer Inc.
DescriptionBivalent meningococcal B vaccine targeting LP2086 (factor H binding protein)
Molecular Target
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine
Latest Stage of DevelopmentMarketed
Standard IndicationMeningitis
Indication DetailsPrevent invasive meningococcal disease caused by Neisseria meningitides serogroup B in 10-18 year olds; Prevent invasive meningococcal disease caused by Neisseria meningitides serogroup B in 10-25 year olds; Prevent invasive meningococcal disease caused by Neisseria meningitides serogroup B in 18-25 year olds; Prevent meningococcal B disease; Treat adult meningitis; Treat and prevent meningitis in infants; Vaccinate against meningococcal disease caused by Neisseria meningitidis serogroup B in adolescents
Regulatory Designation U.S. - Accelerated Approval (Prevent invasive meningococcal disease caused by Neisseria meningitides serogroup B in 10-25 year olds);
U.S. - Breakthrough Therapy (Prevent meningococcal B disease);
U.S. - Priority Review (Prevent invasive meningococcal disease caused by Neisseria meningitides serogroup B in 10-25 year olds)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today